Pfizer (PFE)
(Delayed Data from NYSE)
$27.74 USD
0.00 (0.00%)
Updated Jun 21, 2024 04:02 PM ET
After-Market: $27.75 +0.01 (0.04%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth F Momentum D VGM
Brokerage Reports
Pfizer Inc. [PFE]
Reports for Purchase
Showing records 541 - 560 ( 562 total )
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
First Quarter 2011 Revenue About Even. Non-GAAP EPS Exceeded Consensus Expectations.
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Despite Headwinds in the U.S. and Europe, Fourth Quarter Revenue Exceeded Expectations
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Management raises guidance for CY10 & maintains earlier guidance for CY12....
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Several Factors Held Back Third Quarter Revenue
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Company: Pfizer Inc.
Industry: Large Cap Pharmaceuticals
Acquisition of Wyeth to ease pressure on topline.Earnings growth to bounce back to respectable levels in CY10, on back of effective cost cutting measures & Wyeth related merger synergies.
Provider: FIRST GLOBAL
Analyst: THOMAS K